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Summary
von Hippel–Lindau disease (VHL) is a dominantly in-
herited familial cancer syndrome predisposing to ocular
and CNS hemangioblastomas, renal-cell carcinoma
(RCC), and pheochromocytoma. Both interfamilial and
intrafamilial variability in expression is well recognized.
Interfamilial differences in pheochromocytoma suscep-
tibility have been attributed to allelic heterogeneity such
that specific missense germ-line mutations confer a high
risk for this complication. However, in most cases, tu-
mor susceptibility does not appear to be influenced by
the type of underlying VHL mutation. To probe the
causes of phenotypic variation, we examined 183 indi-
viduals with germ-lineVHL gene mutations, for the pres-
ence and number of ocular tumors. The prevalence of
ocular angiomatosis did not increase with age, and the
distribution of these tumors in gene carriers was signif-
icantly different than the expected stochastic distribu-
tions. Individuals with ocular hemangioblastomas had
a significantly increased incidence of cerebellar heman-
gioblastoma and RCC (hazard ratios 2.3 and 4.0, re-
spectively). The number of ocular tumors was signifi-
cantly correlated in individuals of degree relatedness12
but not in more distantly related individuals. These find-
ings suggest that the development of VHL ocular tumors
is determined at an early age and is influenced by genetic
and/or environmental modifier effects that act at mul-
tiple sites. Functional polymorphisms in the glutathione-
S-transferase M1 gene (GSTM1) or the cytochrome
P450 2D6 gene (CYP2D6) did not show a significant
association with the severity of ocular or renal
involvement.
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Introduction
Familial cancer syndromes, although rare, offer a unique
opportunity to identify the causal factors in human tu-
morigenesis. Most familial cancer syndromes result from
germ-line mutations in tumor-suppressor genes, and the
identification of these genes has provided novel insights
into human tumorigenesis. Variability in clinical ex-
pression is characteristic of these syndromes. In many
cases, phenotypic variation has been correlated with al-
lelic heterogeneity. In addition, genetic or environmental
modifier effects have been implicated in some disorders.
In a mouse model of familial polyposis coli, a modifying
locus has been identified (Mom-1) (Dietrich et al. 1993;
Gould et al. 1996), and the risk of ovarian cancer in
human subjects with BRCA1 mutations appears to be
modified by allelic variation at the H-RAS locus (Phelan
et al. 1996). In a large study of affected relative pairs
with neurofibromatosis type 1, there was significant ev-
idence for modifier effects on the number of cafe´ au lait
spots and neurofibromas (Easton et al. 1993).
von Hippel–Lindau (VHL) disease (OMIM 193300)
is a rare familial cancer syndrome causing susceptibility
to benign vascular tumors of the eye and CNS (angioma
or hemangioblastoma), renal-cell carcinoma (RCC), and
pheochromocytoma (Maher et al. 1990;Maher and Kae-
lin 1997). The gene responsible for VHL has been char-
acterized (Latif et al. 1993) and has been shown to en-
code a protein of 213 amino acids that is ubiquitously
expressed in fetal and adult tissues (Richards et al.
1996). Germ-line mutations have been detected in ∼500
VHL kindred and include deletions of part or whole of
the gene, as well as intragenic point mutations and mi-
crodeletions/insertions (Crossey et al. 1994b; Whaley et
al. 1994; Chen et al. 1995; Zbar et al. 1996). Somatic
inactivating mutations have been identified in tumors
(e.g., cerebellar hemangioblastoma) from VHL-affected
individuals (Prowse et al. 1997) and in sporadic clear-
cell RCC and cerebellar hemangioblastoma (Foster et al.
1994; Gnarra et al. 1994; Kanno et al. 1994; Oberstraß
et al. 1996). Loss of the wild-type VHL allele is frequent
in tumors (including RCC, cerebellar hemangioblas-
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toma, and pheochromocytoma) from VHL patients, and
VHLmethylation occurs both in VHL tumors (RCC and
cerebellar hemangioblastoma) and in sporadic RCC
(Crossey et al. 1994a; Herman et al. 1994; Prowse et
al. 1997; Clifford et al., in press). Interfamilial differ-
ences in predisposition to pheochromocytoma in VHL
disease correlate with the type of germ-line mutation.
Missense VHL gene mutations confer a high suscepti-
bility to pheochromocytoma, and large deletions or pro-
tein-truncating mutations confer a low risk (Crossey et
al. 1994b; Chen et al. 1995; Maher et al. 1996). How-
ever, allelic heterogeneity does not appear to explain the
majority of the tumor-susceptibility variation between
individuals affected by VHL disease (Maher et al. 1996;
A. R. Webster, F. M. Richards, A. T. Moore, and E. R.
Maher, unpublished data).
Unlike other organs affected by VHL disease, the eye
is readily accessible to examination by specialists and
can be scrutinized with high magnification to detect le-
sions as small as 100 mm in diameter. Furthermore, be-
cause these tumors are benign, the presence and position
of previously treated lesions can also be documented.
This allows a unique opportunity for in vivo assessment
of the presence and severity of one manifestation of a
familial cancer syndrome. Using this method, we have
(i) examined the influence of sex and age on VHL ocular
angiomatosis; (ii) determined whether the presence of
ocular angiomatosis in an affected individual affects the
risk of tumors at other sites; (iii) compared the distri-
butions of the number of angiomas versus theoretical
distributions derived from the stochastic nature of so-
matic mutation and previously predicted for retinoblas-
toma (Knudson 1971); (iv) compared pairs of individ-
uals with differing degrees of relatedness, to determine
the presence of shared modifier effects; and (v) tested
our cohort directly for the influence of two genotypes
shown formerly to influence tumor susceptibility.
Subjects and Methods
Ascertainment of Cases
Families and individuals affected by VHL were as-
certained via departments of clinical genetics, ophthal-
mology, and neurosurgery from throughout the United
Kingdom. For each family ascertained, all affected pa-
tients and at-risk relatives were invited to participate so
that as many as possible, if not all, at-risk and affected
individuals from each family were included. In this way
a complete ascertainment was made of most of the VHL
families, without a bias toward the recruiting of either
particularly severely affected individuals or patients pre-
senting to specific specialists. Fully informed consentwas
given by each individual after a full explanation of the
intended research and the nature of the interview and
examination. Ethical approval was provided by the
Cambridge District Ethics Committee.
Patient Interview and Examination
Individuals were examined and interviewed by one or
both of two of the authors (A.R.W. and A.T.M.), and
all were examined by one of the authors (A.R.W.). In-
terview and case-note review included the full docu-
mentation of the individual’s past ocular history and
family history, with particular reference to the presen-
tation, diagnosis, and treatment of the ocular and other
complications of VHL. Examination in each case in-
cluded indirect ophthalmoscopy and slit-lamp biomi-
croscopic fundoscopy. An angioma count of lesions in
each eye was made on the basis of findings on exami-
nation and with reference to case notes. The ocular his-
tory of eyes with no fundal view was determined from
case notes, as far as possible, although an accurate an-
gioma count in these eyes was not possible. A 10-ml
sample of venous blood from each patient was extracted
into EDTA for DNA analysis. The age-related compli-
cations were determined for 16 living affected relatives
and 80 deceased affected relatives for whom accurate
case notes and/or family records were available. These
data, being less accurate than data obtained from ex-
amination and interview, were used only to confirm that
the differences in renal and cerebellar susceptibility re-
mained when all known affecteds were included and to
overcome any ascertainment bias incurred by the exclu-
sion of deceased relatives.
Molecular-Genetic Analysis
VHL mutation detection.—DNA was extracted by
standard methods. The gene-carrier status of patients
was confirmed by the presence of the family mutation
if the latter had been identified; otherwise, family mem-
bers were typed for the informative microsatellite poly-
morphism D3S1038, as described elsewhere (Jones et al.
1992), which has a rate of !1% recombination with the
VHL gene. Specific VHL mutations were determined, as
described (Crossey et al. 1994b; Richards et al. 1994;
Maher et al. 1996). Southern analysis was first per-
formed on blood DNA, to detect/exclude a large deletion
in the VHL gene. A 5-mg sample of genomic DNA was
digested with 1 U of EcoRI (Boehringer Mannheim) at
37C, as recommended by the manufacturers, and then
was run overnight on a 0.8% agarose gel. The DNA
was transferred to a Hybond nitrocellulose filter by stan-
dard methods and hybridized with the VHL cDNA. A
single band of 22 kb is normally detected after auto-
radiography, and a second larger or smaller band iden-
tifies a deletion (Richards et al. 1994). PCR was used
to amplify the VHL coding and promoter region in six
fragments from genomic DNA, and SSCP analysis was
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performed to detect intragenic mutations, as described
elsewhere (Crossey et al. 1994b). Fragments producing
an aberrant SSCP band were purified by use of a Pro-
mega Wizard purification column and were sequenced
on an ABI 373 automated sequencer by dye-terminator
chemistry (AmpliTaq FS), as recommended by the man-
ufacturers. Direct sequencing of the whole coding region
was performed in a similar fashion in those pedigrees in
whom the mutation remained unidentified. All base
changes so found were absent from x200 normal chro-
mosomes. This analysis is expected to identify mutations
in x80% of VHL kindreds (Maher et al. 1996). The
germ-line mutations identified have been described in
detail elsewhere (Crossey et al. 1994b; Richards et al.
1994; Zbar et al. 1996)
Analysis of modifier-gene polymorphisms.—Func-
tional polymorphisms in the glutathione S-transferase
M1 gene (GSTM1) and the cytochrome P450 2D6 gene
(CYP2D6) were analyzed by standard methods. VHL
patients were screened for the GSTM1-null allele poly-
morphism, by a PCR-based assay with three primers,
P1–P3 (Zhong et al. 1993). In this assay, a 230-bp P1–P3
fragment reveals the presence of one or two copies of
the wild-type allele. Absence of the 230-bp fragment
identifies a homozygous-null individual. A control 157-
bp fragment indicates a successful P1–P2 PCR amplifi-
cation from either GSTM1 or the related GSTM4 , in
all individuals. VHL patients were screened, by PCR and
restriction digestion, for the functional polymorphisms
in the CYP2D6 locus (Smith et al. 1992). A high an-
nealing temperature (60C) was used, in order to avoid
having the primers anneal to the homologous genes
CYP2D7 and CYP2D8 (Smith et al. 1992). In the nor-
mal, extensively metabolizing (EM) allele, a BstNI re-
striction site (CCAGG) at the intron 3/exon 4 boundary
allows digestion of the 334-bp PCR product into frag-
ments of 230 bp and 105 bp. However, in the mutated,
poorly metabolizing (PM) allele CYP2D6*4, a GrA
transition causes the loss of this BstNI restriction site
(i.e., the sequence becomes CCAAG). The biological ef-
fect of this mutation is to shift the splice-acceptor se-
quence (AG) at the end of intron 3 so that it is 1 bp
downstream. This leads to the loss of the first G residue
in exon 4 of the processed transcript, with the conse-
quent frameshift mutation causing a premature-termi-
nation codon at nucleotide 554 of the mRNA, hence
preventing translation into a normal CYP2D6 enzyme.
By means of this BstNI assay, patients could by divided
into those with normal CYP2D6 alleles (i.e., EM phe-
notype), heterozygotes, and homozygotes for mutated
CYP2D6*4 alleles (i.e., PM phenotype).
Statistical Methods
Age-related prevalence.—Prevalence of ocular an-
giomatosis was calculated both for the whole cohort and
separately for five age groups of gene carrier (ages 0–19
years, 20–29 years, 30–39 years, 40–49 years, and x50
years). Confidence intervals were calculated for the prev-
alence of each group, and a point–age-related prevalence
was determined by use of the mean age in each group.
The observed prevalence data were tested against two
theoretical models:
1. A “constant risk” model assuming a constant risk
per unit time, throughout life, that a gene carrier will
convert from having bilateral healthy retinas to having
one or more ocular angiomas. Under such a condition
the relationship between prevalence (y) and age (x)
would be of the form , where m and mm(xm)y  1 e
are constants with dimensions time1 and time1, respec-
tively. The value of m was fixed at 0.75 years, to fix a
value of 0 prevalence at conception. The constantmwas
varied between the limits 0.055 and 0.130 years1, to
generate a group of curves to fit within the 95% con-
fidence interval (95% CI) of the actual prevalence of the
youngest age group (0–19 years; ; prevalence .70,n  34
),95%CI  .55–.85
2. A fixed prevalence model assuming that ocular le-
sions are congenital and that prevalence is fixed through-
out life.
One likely cause for the lower than expected preva-
lence in surviving older gene carriers compared with
younger ones is that patients with ocular angiomatosis
have generally more severe disease and therefore die ear-
lier from systemic complications.We therefore examined
whether our data were consistent with the null hypoth-
esis that each model was operating and that, by a certain
age, all deceased gene carriers would have had ocular
angiomatosis. To do this, we calculated a theoretical
proportion of survivors who would be seen to have oc-
ular angiomatosis (at) under this hypothesis, as follows:
, where st is the survival proportiona  (p  s  1)/st t t t
at age t (by survival analysis of 279 gene carriers from
the 81 pedigrees included in this study; data not shown)
and pt is the proportion of all individuals (dead and alive)
who either are or would have been affected by ocular
angiomatosis at age t (calculated on the basis of the
models described above). The calculated prevalences un-
der this hypothesis were compared with our data for
each of the age groups, and the null hypothesis was
rejected if the calculated theoretical prevalence was out-
side the 95% CIs of the actual data.
Distributions of number of angiomas and affected eyes
in gene carriers.—Molecular-genetic studies of VHL tu-
mors have shown loss of heterozygosity andmethylation
of the wild-type allele. If the development of VHL tu-
mors is similar to that in retinoblastoma (a two-hit
model), the development of a tumor from any one found-
ing retinal cell depends on a somatic VHL mutation in
that cell. Even if there were no external influences on
tumorigenesis, variation would occur purely because of
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the stochastic nature of these mutational events. In the
absence of other influences, the distribution of the num-
ber of individuals having each discrete number of ocular
tumors in their eyes, when the mean number of ocular
tumors per individual in the population is, say,m,would
follow a Poisson distribution with parameter m
. Similarly, the distribution of the number of in-Po(m)
dividuals having each number of eyes suffering from one
or more ocular angioma (none, one, or two), in a sample
of n people with a total of x eyes affected, would follow
a binomial distribution with parameters Bin(2,x/2n).
These two theoretical distributions were calculated for
the cohort of individuals in this study and were com-
pared with the actual observed distributions, by the x2
test for goodness of fit. To compensate for any age-re-
lated effects that may affect the independence of obser-
vations (e.g., premature death of angioma-positive cases
and differing age-related prevalence), similar analysis
was also performed on restricted age groups.
Cumulative prevalence of cerebellar and renal disease
in angioma-positive and -null individuals.—Since the di-
agnosis of the complications that occur in VHL is age
dependent, in previous studies we had used survival
analysis to compare the age-related cumulative preva-
lence for a specific complication in two or more groups
of individuals (Maher et al. 1990, 1996). Both to analyze
the association between ocular angiomatosis and cere-
bellar and renal complications and to compensate for
patient age, we have used a similar analysis in the present
study. Patients were divided into groups on the basis of
their ocular status at the time of the study. For each
group and for each year of analysis (y), the cumulative
probability of having incurred a cerebellar or renal com-
plication was calculated as follows: cumulative proba-
bility  , where py1 is the prob-1 [p ∗ (r  f )/r ]y1 y y y
ability that an individual will survive, without the
complication, to year , ry is the number of individ-y 1
uals still at risk at year y, and fy is the number of indi-
viduals incurring the complication at year y. The log-
rank test and the log-rank test for trend were used to
assess the significance of differences between groups.
Relative-pair analysis.—To determine whether the de-
gree of ocular angiomatosis was influenced by factors
shared by related individuals, we generated pairs of af-
fected individuals of differing degrees of relatedness. We
also generated pairs of unrelated individuals who were
known to share exactly the same underlying germ-line
VHL mutation. Pairwise correlation coefficients were
calculated for the number of ocular angiomas. Because
the distribution of the number of ocular angiomas in
affecteds is highly skewed, the data were transformed
by use of the function log( ). This is similar to the1 x
analysis used by previous studies in the analysis of the
neurofibromatosis 1 phenotype (Easton et al. 1993). To
test the significance of specific pairwise correlations, the
following statistic was calculated: ,2 t  r n 2/ 1 r
where r is the Pearson correlation coefficient and n is
the number of pairs. t is distributed as a t distribution
with df, under the assumption that there is non 2
correlation. We used a null hypothesis of no positive
correlation, thus using a one-tailed test of significance
for each group of pairs.
Effect of GSTM1 and CYP2D6 on ocular angiomato-
sis.—The proportion of patients with angiomawhowere
in the different genotype groups (GSTM1 null vs. other;
CYP2D6 EM vs. other) were compared, by the x2 test
for independence, for the null hypothesis that angioma
status is independent of genotype. Furthermore, groups
of patients with increasing numbers of ocular angiomas
in these same groups were examined by x2 for trend. To
determine whether one or more specific combination of
genotypes at these two loci (six genotypes in all) might
have a significant effect through their interaction, the six
genotypes were tested against the null hypothesis that
all were similar with regard to their effect on the number
of angiomas, by nonparametric analysis of variance
(Kruskall-Wallis).
The cumulative probability of a solid renal lesion was
calculated by survival methods (see above), for the com-
parisons GSTM1 null versus other and CYP2D6 EM
versus other. To control for the potential confounding
effect of ocular angiomatosis, each group was stratified
for the presence or absence of ocular angiomatosis, and
the stratified log-rank test was used to compare groups.
Results
Patient Details
A total of 183 gene carriers were identified through
clinical and molecular genetic criteria and were inter-
viewed and examined as described above (mean age 33.8
years, range 7–74 years; 101 males [ ]). FamiliesP  .15
originated from all over the United Kingdom, including
Scotland and Northern Ireland. Patients were derived
from 81 unrelated pedigrees (mean number of affected
examined members per pedigree 2.3, range 1–10). Clin-
ical details were collected from case notes and relatives’
interviews, for 80 deceased affecteds and 16 living af-
fecteds who were unavailable for interview (56 males
and 40 females [ ]). By means of survival analysisP  .08
for all affected individuals in these 81 pedigrees, the
median survival was calculated as 57 years.
Sex- and Age-Related Prevalence of Ocular
Angiomatosis in VHL
The overall prevalence of ocular angiomatosis in 183
examined gene carriers was 68%. The prevalence of oc-
ular angiomatosis was similar in males and females
(65% in males and 71% in females [not sig-2x  0.361
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Figure 2 The actual prevalence of ocular angiomatosis (95%
CI) in over 30 year old affected VHL patients. Against these are four
calculated values of the prevalence of ocular angiomatosis in survivors
assuming that all deceased VHL patients had ocular angiomatosis and
(i) a constant risk of developing ocular angiomatosis is present
throughout life and (ii) the prevalence of ocular angiomatosis is fixed
from birth.
Figure 1 The prevalence of ocular angiomatosis (95% CI) in
the cohort of 183 affected VHL patients for different age groups. The
two superimposed curves are derived from the expected prevalence
that would occur if the chance of converting to having ocular an-
giomatosis remained constant throughout life.
nificant]). The mean number of ocular angiomas in
males and females in whom an accurate bilateral count
was possible did not significantly differ (mean 1.78 in
88 males and mean 1.94 in 68 females [not significant]).
The mean age of patients with ocular angiomatosis (32.2
years in 124 patients) was lower than the mean age of
patients without (37.0 years in 59 patients), and this
was statistically significant ( ; , two-T  2.14 P ! .013181
tailed). The prevalence of ocular angiomatosis in differ-
ent age groups is shown in figure 1. Curves for a con-
stant-risk model were constructed (see Statistical Meth-
ods subsection) and were plotted togetherwith the actual
data (the age used is the mean age of the group). Figure
1 also shows two curves ( and )m  0.055 m  0.130
that fit within the 95% CIs of the prevalence of the
youngest age group. Neither of these curves lies within
the 95% CIs of the observed prevalence of the older age
groups.
One likely explanation for the reduction in prevalence
of ocular angiomatosis in the older gene carriers is the
selective death of angioma-positive patients because they
generally have a more severe type of the disease (see
below). A theoretical prevalence of ocular angiomatosis
in survivors for the three oldest age groups was calcu-
lated (see Statistical Methods subsection) by use of the
following models: (i) a constant-risk model with m 
and and (ii) models using a fixed prev-0.055 m  0.130
alence of .75 and .83, as shown with the actual data in
figure 2. The calculated values for the constant-riskmod-
els fall well outside the actual 95% CIs. Therefore, even
when a correction is made for the selective early death
of angioma-positive patients, the age-related prevalence
of angiomatosis does not concord with the hypothesis
that the probability of angiomatosis development is a
constant throughout life. Alternatively, the theoretical
prevalence in survivors that is generated under the as-
sumption of a fixed-prevalence model does fit within the
95% CIs of the actual data. Hence, the data are com-
patible with the ocular lesions being present at an early
age and having a fixed prevalence thereafter.
Distribution of Number of Ocular Angiomas in VHL
Carriers
If the probability of an angioma originating from a
susceptible retinal cell in a VHL carrier is a rare, inde-
pendent event, then the number of angiomas occurring
in gene carriers should conform to a Poisson distribution
(as has been reported for retinoblastoma) (Knudsen et
al. 1971). Factors that would cause deviation from such
a distribution include an influence of age, type of un-
derlying germ-line mutation, or other genetic risk- or
environmental risk-modifying factors. For the 183 gene
carriers, an accurate angioma count was possible in 155.
The mean number of angiomas occurring per affected
individual was 1.83. The observed distribution was sig-
nificantly different than a Poisson distribution with the
same mean ( ; ). Of the remaining2x  82.1 P K .00014
28 patients, 16 of 22 unilaterally blind individuals had
accurate case records concerning the number of angio-
mas occurring in the blind eye. The distribution of the
total number of angiomas in these 171 gene carriers is
shown in figure 3. Superimposed is the theoretical Pois-
son distribution with the same mean (Po[2.1]; mean no.
of angiomas 2.1). Clearly, the distribution of angiomas
does not conform to a Poisson distribution, the differ-
ence being significant ( ; ). If the2x  117.5 P K .00014
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Figure 3 The actual distribution of the number of ocular an-
giomas in affected patients drawn against the theoretical Poisson dis-
tribution with the same mean.
Figure 4 The cumulative probability of a first symptomatic cer-
ebellar lesion occurring in the cohort of VHL patients divided into
two groups on the basis of the presence of ocular angiomatosis
outliers with x10 angiomas are omitted from the anal-
ysis, the mean number of angiomas is reduced to 1.79,
but the data remain significantly different from a Poisson
distribution with this mean. These most severely affected
patients were unrelated and did not share the same VHL
germ-line mutation. The distribution remains non-Pois-
son when the data are restricted to a narrow age range
(e.g., 20–39 years) (mean 2.79 in 85 individuals; 2x 5
; ). Also, the inclusion, within such a66.92 P K .0001
cohort of surviving patients, of the expected number
of patients who would have suffered VHL-related
deaths—and the assignment to each such patient of one
or more angiomas—would not compensate for the num-
ber of individuals with no angiomas, to allow the dis-
tribution to fit a Poisson curve (data not shown). It can
be concluded, therefore, that the variability in the num-
ber of angiomas in the eyes of VHL patients is not due
to stochastic factors alone.
Distribution of Number of Affected Eyes in Gene
Carriers
In a similar way, if the event of a gene carrier’s eye
becoming angiomatous is independent with regard to
the fate of the fellow eye and has a probability that is
shared among all gene carriers, then the number of eyes
(zero, one, or two) affected by angiomatosis should fit
the binomial distribution Bin(2,p), where p is the mean
probability of angiomatosis occurring in an eye of a gene
carrier. Of the 183 patients, angiomatosis occurred in
199 eyes. The estimated mean probability that an eye
in a gene carrier will suffer angiomatosis is, therefore,
. The observed distribution for 183199/ (183 ∗ 2)  .54
affected patients was as follows: angiomatosis in neither
eye, 59 patients; angiomatosis in one eye, 49 patients;
and angiomatosis in both eyes, 75 patients. The theo-
retical binomial distribution for the number of eyes af-
fected in patients is Bin(2,.54) and would give a theo-
retical distribution of (angiomatosis in neither eye, 39
individuals; angiomatosis in one eye, 91 individuals; and
angiomatosis in both eyes, 53 individuals); this is sig-
nificantly different from the observed data ( 2x 1
; ). There is also significant difference39.62 P ! .005
when only patients restricted to a narrow age group are
included (e.g., 20–39 years [theoretical Bin(2,.62);
; ]). These findings suggest that the2x  20.17 P ! .0051
probability of an eye being affected is not independent
of the state of the fellow eye, and the excess of pairs of
eyes that are both either affected or unaffected suggests
that other factors in addition to the stochastic nature of
tumorigenesis influence the variation in tumor
susceptibility.
Effect of Status of Ocular Angioma on Susceptibility to
Other Tumors
Survival curves for the cumulative risk of development
of a first symptomatic cerebellar lesion were constructed
for individuals with and without ocular angiomatosis
(fig. 4). The occurrence of ocular angioma significantly
increased the susceptibility to cerebellar hemangioblas-
toma (log-rank test ; ), the hazard ra-2x  7.48 P ! .0061
tio being 2.3. The occurrence of ocular angioma also
significantly increased the susceptibility to a first solid
renal lesion (fig. 5) (log-rank test ;2x  11.15 P !1
), the hazard ratio being 4.0. These differences.0008
were still significant when retrospective data from 96
unexamined individuals (80 of whom were deceased)
from the same pedigrees were included (data not shown).
Furthermore, there was a significant increase in the sus-
ceptibility to a first symptomatic cerebellar lesion when
individuals were divided into three groups on the basis
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Figure 5 The cumulative probability of a first solid renal lesion
occurring in the cohort of VHL patients divided into two groups on
the basis of the presence of ocular angiomatosis
Figure 6 The cumulative probability of a first symptomatic cer-
ebellar lesion occurring in the cohort of VHL patients divided into
three groups on the basis of the presence of 0, 1-2, 12 ocular tumors.
of the degree of ocular angiomatosis (i.e., no angiomas,
one or two angiomas, and more than two angiomas)
and were examined for trend (fig. 6) (log-rank test for
trend ; ). With regard to renal lesions,2x  9.09 P ! .0031
the majority of individuals were screened for this com-
plication, according to a standard protocol (Maher et
al. 1990). The small proportions not screened were sim-
ilar in the angioma-positive and -null groups and so did
not confound this analysis.
A similar analysis, comparing the cumulative proba-
bility of symptomatic cerebellar lesions in those with a
previous solid renal lesion (38 individuals, 75% prob-
ability at 60 years of age) and in those without it (145
individuals, 66% probability at 60 years of age), showed
a greater susceptibility in those who had had a renal
lesion diagnosed, although this did not reach statistical
significance (log-rank test ).P 1 .05
Modifier Effects in Ocular Angiomatosis
Table 1 shows the results of pairwise correlation co-
efficients for the number of ocular angiomas occurring
in pairs of relatives of different degrees of relatedness.
It can be seen that the correlation was significantly pos-
itive, at the 5% level, only in pairs of relatives who
would be expected to share half their genome, both in
parent-child pairs and in sib pairs. No significant positive
correlation was seen in other relative pairs, despite a
similar sample size (and, hence, similar statistical
power). Furthermore, pairs of individuals not knowingly
related who had the same underlying mutation did not
show significant positive correlation. Mutations were
deemed identical only if the same-size abnormal frag-
ments were detected on Southern analysis or, alterna-
tively, if the same nucleotides were involved in intragenic
mutation.We have reported elsewhere that, in theUnited
Kingdom, most families with identical mutations do not
share a similar haplotype, suggesting that there is not a
common ancestry (Richards et al. 1995).
GSTM1 and CYP2D6 Genotype and Ocular
Angiomatosis
A total of 163 VHL patients were typed successfully
forGSTM1-allele status. Of these, 75 (46%)were shown
to have a 230-bp fragment as well as the control 157-
bp fragment and therefore possessed a functional
GSTM1 allele. The remaining 88 (54%) demonstrated
only the control, 157-bp fragment and therefore were
identified as homozygous nulls. The proportion of pa-
tients affected by ocular angiomatosis was not signifi-
cantly different in the two groups—GSTM1-positive
group, 54/75 (72%); GSTM1-null group, 57/88 (65%)
( ; ). Of the 163 VHL patients typed2x  0.67 P  .411
for GSTM1-allele status, an accurate bilateral angioma
count was available in 151. The mean number of an-
giomas in patients from each group was not significantly
different (GSTM1 positive, 2.30; GSTM1 null, 2.04
[ , not significant). Furthermore, when theT  0.59138
data were examined for trend, there was no influence of
the GSTM1 genotype on the number of angiomas in
patients ( , not significant). These results are2x  0.121
shown in table 2.
A total of 161 VHL patients were typed successfully
for the CYP2D6 genotype; 99 (61.5%) of them were
homozygous for the PM allele of CYP2D6, 51 (31.7%)
of them were identified as heterozygotes, and 11 (6.8%)
of them were PM. The proportion of patients affected
by ocular angiomatosis was not significantly different in
patients homozygous for the EM allele of CYP2D6
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Table 1
Correlation Coefficients for Number of Ocular Angiomas in Pairs
of Affected Patients of Differing Degrees of Relatedness
Relative Pair (No.)
Degree of
Relatedness Correlation Pa
Pairs of patients’ eyes (155) 1 .56 !.0001
Parent-child pair (45) 1/2 .27 .04
Siblings (53) 1/2 .32 .01
1 in 4 (48) 1/4 .14 .16
X1 in 8 (45) !1/8 .08 NS
Unrelated (49) .21 NS
a NS  not significant.
Table 2
Numbers of Affected Patients with Ocular Angiomas Counts, by
GSTM1 and CYP2D6 Genotype
NO. OF
ANGIOMAS
NO. OF PATIENTS
GSTM1 CYP2D6
Null Positive Total EM Heterozygous/PM Total
0 31 21 52 35 16 51
1 13 17 30 18 12 30
2 10 9 19 10 9 19
3–4 12 14 26 14 11 25
x5 14 10 24 14 10 24
Total 80 71 151 91 58 149
(64%), compared with either the heterozygotes or the
PM individuals (74%) ( ; ). Of the 1612x  1.19 P  .271
VHL patients typed for CYP2D6-allele status, an ac-
curate bilateral angioma count was available in 149. The
mean number of angiomas in patients from each group
did not significantly differ (EM individuals, 2.13; het-
erozygotes or PM individuals, 2.22 [ , not sig-T  0.21140
nificant). Furthermore, when the data were examined
for trend, there was no influence of the CYP2D6 ge-
notype on the number of angiomas in patients ( 2x 1
; ). These results are shown in table 2.1.23 P  .26
To determine whether a specific combination of
GSTM1 and CYP2D6 genotypes either was protective
or caused particular susceptibility with regard to ocular
angiomatosis, we divided the 149 patients into the six
genotype groups (null/EM [42 individuals], null/hetero-
zygous [27 individuals], null/PM [3 individuals], posi-
tive/EM [42 individuals], positive/H heterozygous [20
individuals], and positive/PM [8 individuals]). We then
performed nonparametric analysis of variance (Kruskall-
Wallis) on all the data. The data did not significantly
differ from those expected under the null hypothesis that
none of the six individual groups were significantly pro-
tective or caused more susceptibility to ocular angiom-
atosis than the cohort as a whole ( ; ).2x  2.27 P  .131
GSTM1 and CYP2D6 Genotypes and RCC
To determine whetherGSTM1 or CYP2D6 status had
an effect on the diagnosis of a first solid renal lesion,
survival analysis was used. To overcome the potential
confounding effect of ocular angioma, each group was
stratified with regard to the presence or absence of ocular
angiomatosis. When the stratified log-rank test was used,
there was no significant difference, in the development
of a first solid renal lesion, either between patients with
a GSTM1-null genotype (88 individuals) and patients
with a GSTM1-positive genotype (75 individuals)
( ; ) or between patients homozygous for2x  1.78 P 1 .11
the EM allele of CYP2D6 (99 individuals) and patients
either heterozygous or homozygous for the PM allele
(62 individuals) ( , not significant).2x  0.0391
Discussion
Variable expression is a feature of many genetic dis-
orders and may result from either allelic heterogeneity
or the influence of environmental and modifying genetic
factors. In inherited cancer syndromes caused by germ-
line mutations in tumor-suppressor genes such as RB1,
tumors occur through the chance event of one or more
somatic mutations in a susceptible cell, and variability
will also occur solely because of this stochastic mecha-
nism. Molecular studies of VHL tumors (e.g., cerebellar
hemangioblastoma and RCC) suggest a tumorigenesis
model similar to that for retinoblastoma (Crossey et al.
1994a; Prowse et al. 1997). However, for retinal he-
mangioblastomas in VHL disease, we have shown that
there is a significant deviation from the theoretical sto-
chastic distributions, in both the number of individual
tumors and the number of affected eyes, in individuals
with VHL disease. It is of interest that, in Knudson’s
(1971) original work on retinoblastoma, Poisson and
binomial distributions were assumed in the analysis of,
respectively, the number of retinoblastoma tumors and
the number of affected eyes from data on familial reti-
noblastoma cases. As far as we are aware, this is the
first time that such assumptions have been tested em-
pirically, and we find that, for ocular angiomatosis in
VHL disease, these assumptions are incorrect. Thus the
stochastic nature of tumorigenesis cannot fully account
for the variability of ocular involvement in VHL disease,
and other factors therefore must be important (or a dif-
ferent model of tumorigenesis is operating).
If the risk of development of ocular angioma in VHL
disease were lifelong, then the mean age of individuals
affected by this manifestation would be expected to be
higher than that of those not affected. In the present
study, however, VHL gene carriers with ocular angioma-
tosis were significantly younger than those without it.
In a cross-sectional study such as this, individuals of
different ages are sampled simultaneously. One expla-
nation for this observation, therefore, is that, with regard
to their exposure to environmental mutagens, younger
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subjects differ from those born earlier. We propose that
an alternative explanation is that patients with retinal
involvement are more likely to suffer the other major
complications of the disease. In the present study, we
found that the major complications of VHL disease are
not independent of each other. Individuals with ocular
angiomatosis were 2.3 and 4 times more susceptible to
development of cerebellar and renal lesions, respectively.
Since these complications are a cause of mortality in
VHL, older surviving individuals are more likely to be
generally less severely affected and, therefore, more
likely to be free of ocular angiomatosis. Although a sim-
ilar analysis showed that subjects who had renal lesions
were more likely to have suffered cerebellar lesions, this
was not statistically significant. This may be because,
unlike our analysis of ocular involvement, this compar-
ison relies wholly on retrospective data and therefore is
likely to be less accurate.
The age-related prevalence observed in this cohort of
gene carriers was not consistent with a theoretical model
of a constant risk, throughout life, of conversion from
the presence of normal eyes to eyes with one or more
ocular tumors. This inconsistency remained after a cor-
rection based on the assumption that all deceased VHL
individuals had been affected by ocular angiomatosis.
Hence, our data suggest that the risk of development of
ocular angiomatosis is not lifelong. This would be con-
sistent with the hypothesis that an ocular angioma will
develop only if the important tumorigenic somatic mu-
tations occur during a specific time interval. This situ-
ation would be similar to that of familial and sporadic
retinoblastoma, as well as to that of other childhood-
related tumors, but is apparently different from that of
most familial and sporadic adult cancers. The data
would also be compatible with the ocular lesions being
congenital hamartomas, a view supported also by the
fact that, histologically, the tumors have three distinct
cell types.
The relationship between visual acuity and the pres-
ence of ocular angiomatosis is not straightforward, and
the reasons why some, but not all, lesions cause ocular
complications leading to loss of vision are unknown. The
present study did not address this issue. However, the
data presented here suggest that adult gene carriers who
are free of angiomatosis are likely to be at low risk of
development of further retinal angiomas.
Previous studies of genotype-phenotype correlations
in VHL have shown an association between deletions/
protein-truncating mutations and a low risk of pheo-
chromocytoma (Crossey et al. 1994b; Chen et al. 1995;
Maher et al. 1996). Also, a specific missense mutation
has been associated with a low risk of RCC (Brauch et
al. 1995), although this mutation did not occur in the
pedigrees included in this study. Otherwise, ocular, CNS,
and renal involvement are not influenced by the type of
underlying germ-line mutation (Maher et al. 1996).With
regard to ocular angioma, this result is supported by the
data in this study, in the lack of correlation between
pairs of distantly related individuals despite the fact that
the latter have identical mutations. Closely related in-
dividuals, however, did show a significant correlation
with regard to the number of ocular angiomas. This was
evident only in relative pairs who share half the genome,
being apparent in both sib pairs and parent-child pairs.
This suggests that important modifying factors might be
shared between closely related individuals. Furthermore,
since the risks of cerebellar hemangioblastoma and RCC
were increased in patients with retinal angiomatosis,
these modifying factors appear to influence susceptibility
to each of the three major complications of VHL disease.
The putative modifiers could be genetic and/or envi-
ronmental. However, genetic factors are likely to be in-
volved, since, because of differences in age, parent-sib
pairs would not preferentially share environmental fac-
tors. Candidate modifiers in VHL disease would include
factors that determine the clearance of environmental
mutagens from the body and the rate at which tumor-
igenic metabolites are generated from inactive procar-
cinogens. Although specific environmental mutagens
that predispose to ocular hemangioblastomas have not
been identified, functional polymorphisms in GSTM1
and CYP2D6 have been implicated in cancer suscepti-
bility (for reviews, see Wolf et al. 1994; Raunio et al.
1995). Foreign compounds are metabolized in two
stages (phase I and phase II metabolism). Phase I is usu-
ally an oxidation step giving rise to an electrophilic in-
termediate that may be mutagenic. Phase II enzymes cat-
alyze the conjugation of specific chemical groups (e.g.,
glutathione) to previously created electrophilic inter-
mediates, to produce a water-soluble metabolite that is
excreted. Individuals with efficient phase I metabolism
and inefficient phase II enzymes would be predicted to
be predisposed to cancer when they are exposed to ap-
propriate carcinogens. Approximately 50% of the pop-
ulation are homozygous null for the phase II enzyme
GSTM1, and the null phenotype has been associated
with susceptibility to colorectal, bladder, and squamous-
cell lung cancer (Zhong et al. 1991, 1993; Daly et al.
1993). Similarly, polymorphic variations in the cyto-
chrome P450 2D6 (CYP2D6) gene (a phase I enzyme)
may produce EM individuals or PM individuals. Ap-
proximately 66% of the Caucasian population are EM,
30% are heterozygous, and 4% are PM, with 80%–90%
of PM alleles being theCYP2D6*4 (G1934A) frameshift
mutation detected by BstNI digestion (Smith et al. 1992;
Sachse et al. 1997). The EM genotype may predispose
to lung and liver cancer (Hirvonen et al. 1993; Agundez
et al. 1995, 1996). However, we found no evidence to
suggest that, in patients affected by VHL disease, allelic
variation at either GSTM1 or CYP2D6 modifies either
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the number of retinal angiomas or the age at develop-
ment of a first solid renal lesion. Nevertheless, the iden-
tification of such modifying factors would extend our
understanding of the mechanisms of tumorigenesis and
would improve the accuracy of tumor-risk predictions
in patients with VHL disease.
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